Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
10 "Chul-Kee Park"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
To Use or Not to Use: Temozolomide in Elderly Patients with IDH Wild-type MGMT Promoter Unmethylated Glioblastoma Treated with Radiotherapy
Chan Woo Wee, Joo Ho Lee, Hye In Lee, Jina Kim, Jong Hee Chang, Seok-Gu Kang, Eui Hyun Kim, Ju Hyung Moon, Jaeho Cho, Chul-Kee Park, Chae-Yong Kim, Kihwan Hwang, Hong In Yoon, In Ah Kim
Received September 27, 2024  Accepted November 9, 2024  Published online November 11, 2024  
DOI: https://doi.org/10.4143/crt.2024.945    [Accepted]
AbstractAbstract PDF
Purpose
To identify a specific subgroup of patients among elderly glioblastoma patients aged 70 years or older with unmethylated MGMT promoters (eGBM-unmethylated) who would significantly benefit from the addition of temozolomide (TMZ) to radiotherapy (RT).
Materials and Methods
Newly diagnosed patients with IDH wild-type eGBM-unmethylated treated with RT were included in this multicenter analysis (n=182). RT dose was 45 Gy in 15 fractions (62.3%), 60 Gy in 30 fractions, or 61.2 Gy in 34 fractions. For patients treated with RT plus TMZ (60.4%), TMZ was administered concurrently with RT, followed by six adjuvant cycles. The primary endpoint was overall survival.
Results
During a median follow-up of 11.3 months for survivors, the median survival was 12.2 months. The median survival duration significantly improved with the addition of TMZ to RT compared with that with RT alone (13.6 months vs. 10.5 months, p=0.028). In the multivariable analysis adjusted for clinical, radiological, and genetic biomarkers, the addition of TMZ significantly improved overall survival (hazard ratio, 0.459; p=0.006). In subgroup analysis, median survival was especially improved by 4–5 months in patients with residual disease (p<0.001), Karnofsky Performance Status ≥60 (p=0.033), and age ≤75 years (p=0.090). A significant benefit of TMZ was noted only in patients with two or three of the above factors (median survival, 14.1 months vs. 10.5 months, p=0.014).
Conclusion
The addition of TMZ significantly improved the survival of patients with eGBM-unmethylated treated with RT. The suggested criteria for the specific subgroup in these patients warrant external validation for clinical application.
  • 25 View
  • 3 Download
Close layer
CNS cancer
The Role of Postoperative Radiotherapy in Intracranial Solitary Fibrous Tumor/Hemangiopericytoma: A Multi-institutional Retrospective Study (KROG 18-11)
Joo Ho Lee, Seung Hyuck Jeon, Chul-Kee Park, Sung-Hye Park, Hong In Yoon, Jong Hee Chang, Chang-Ok Suh, Su Jeong Kang, Do Hoon Lim, In Ah Kim, Jin Hee Kim, Jung Ho Im, Sung-Hwan Kim, Chan Woo Wee, Il Han Kim
Cancer Res Treat. 2022;54(1):65-74.   Published online March 24, 2021
DOI: https://doi.org/10.4143/crt.2021.142
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to evaluate the role of postoperative radiotherapy (PORT) in intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC).
Materials and Methods
A total of 133 patients with histologically confirmed HPC were included from eight institutions. Gross total resection (GTR) and subtotal resection (STR) were performed in 86 and 47 patients, respectively. PORT was performed in 85 patients (64%). The prognostic effects of sex, age, performance, World Health Organization (WHO) grade, location, size, Ki-67, surgical extent, and PORT on local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) were estimated by univariate and multivariate analyses.
Results
The 10-year PFS, and OS rates were 45%, and 71%, respectively. The multivariate analysis suggested that PORT significantly improved LC (p < 0.001) and PFS (p < 0.001). The PFS benefit of PORT was maintained in the subgroup of GTR (p=0.001), WHO grade II (p=0.001), or STR (p < 0.001). In the favorable subgroup of GTR and WHO grade II, PORT was also significantly related to better PFS (p=0.028). WHO grade III was significantly associated with poor DMFS (p=0.029). In the PORT subgroup, the 0-0.5 cm margin of the target volume showed an inferior LC to a large margin with 1.0-2.0 cm (p=0.021). Time-dependent Cox proportion analysis showed that distant failures were significantly associated with poor OS (p=0.003).
Conclusion
This multicenter study supports the role of PORT in disease control of intracranial SFT/HPC, irrespective of the surgical extent and grade. For LC, PORT should enclose the tumor bed with sufficient margin.

Citations

Citations to this article as recorded by  
  • Development of an MRI‐Based Comprehensive Model Fusing Clinical, Radiomics and Deep Learning Models for Preoperative Histological Stratification in Intracranial Solitary Fibrous Tumor
    Xiaohong Liang, Kaiqiang Tang, Xiaoai Ke, Jian Jiang, Shenglin Li, Caiqiang Xue, Juan Deng, Xianwang Liu, Cheng Yan, Mingzi Gao, Junlin Zhou, Liqin Zhao
    Journal of Magnetic Resonance Imaging.2024; 60(2): 523.     CrossRef
  • Meningeal Solitary Fibrous Tumor: A Single-Center Retrospective Cohort Study
    Siyer Roohani, Yasemin Alberti, Maximilian Mirwald, Felix Ehret, Carmen Stromberger, Soleiman Fabris Roohani, Katja Bender, Anne Flörcken, Sven Märdian, Daniel Zips, David Kaul, Manish Charan
    Sarcoma.2024; 2024: 1.     CrossRef
  • Repeated Radiation Therapy of Recurrent Solitary Fibrous Tumors of the Brain: A Medical Case History Over 20 Years
    Anna Carla Piccardo, Sabrina Gurdschinski, Sybille Spieker, Christof Renner, Piotr Czapiewski, Markus Wösle, I. Frank Ciernik
    Advances in Radiation Oncology.2024; 9(4): 101426.     CrossRef
  • Intracranial solitary fibrous tumors: Clinical, radiological, and histopathological insights along with review of literature
    Adil Aziz Khan, Sana Ahuja, Dipanker Singh Mankotia, Sufian Zaheer
    Pathology - Research and Practice.2024; 260: 155456.     CrossRef
  • Central nervous system solitary fibrous tumors: Case series in accordance with the WHO 2021 reclassification. Framework for patient surveillance
    V. Matthijs, R. Beckers, C. Vanden Broecke, F. Dedeurwaerdere, J. Van Dorpe, D. Vanhauwaert, G. Hallaert
    Acta Neurochirurgica.2024;[Epub]     CrossRef
  • Recurrence of Solitary Fibrous Tumor in the Spinal Cord Following Gross Total and Subtotal Resection: A Case Report of Recurrence 19 Years of Post-total Resection and Systematic Literature Review
    Satoka SHIDOH, Kazutoshi HIDA, Yoshitaka ODA, Toru SASAMORI, Prabin SHRESTHA, Jangbo LEE, Satoshi YAMAGUCHI
    NMC Case Report Journal.2024; 11: 297.     CrossRef
  • The Role of Radical Radiotherapy in Sinonasal Myopericytoma: A Case Report and Literature Overview
    Anna Merlotti, Stefania Martini, Riccardo Vigna Taglianti, Alessia Reali, Giuseppe Signorini, Silvana Parisi, Francesca De Felice
    EMJ Oncology.2023;[Epub]     CrossRef
  • Intracranial Solitary Fibrous Tumour Management: A French Multicentre Retrospective Study
    Marine Lottin, Alexandre Escande, Luc Bauchet, Marie Albert-Thananayagam, Maël Barthoulot, Matthieu Peyre, Mathieu Boone, Sonia Zouaoui, Jacques Guyotat, Guillaume Penchet, Johan Pallud, Henry Dufour, Evelyne Emery, Michel Lefranc, Sébastien Freppel, Houm
    Cancers.2023; 15(3): 704.     CrossRef
  • Solitary fibrous tumor of the central nervous system invading and penetrating the skull: A case report
    Qiyan Lin, Jiabin Zhu, Xiaofeng Zhang
    Oncology Letters.2023;[Epub]     CrossRef
  • Impact of extent of resection and postoperative radiotherapy on survival outcomes in intracranial solitary fibrous tumors: a systematic review and meta-analysis
    Sae Min Kwon, Min Kyun Na, Kyu-Sun Choi, Tae Ho Lim, Hyungoo Shin, Juncheol Lee, Heekyung Lee, Wonhee Kim, Youngsuk Cho, Jae Guk Kim, Chiwon Ahn, Bo-Hyoung Jang
    Neurosurgical Review.2023;[Epub]     CrossRef
  • Radiotherapy for rare primary brain tumors
    E. Mesny, P. Lesueur
    Cancer/Radiothérapie.2023; 27(6-7): 599.     CrossRef
  • Complete Resection of a Torcular Herophili Hemangiopericytoma without Sinus Reconstruction: A Case Report and Review of the Literature
    Salah-Edine Safi, Julie Godfrain, Herbert Rooijakkers, Frederic Collignon, Mario Ganau
    Case Reports in Surgery.2023; 2023: 1.     CrossRef
  • Surgical Management of Craniospinal Axis Solitary Fibrous Tumors: A Single-Institution Case Series and Comprehensive Review of the Literature
    Anthony J. Piscopo, A. J. Chowdhury, Nahom Teferi, Sarah Lee, Meron Challa, Michael Petronek, Kathryn Eschbacher, Girish Bathla, John M. Buatti, Patrick Hitchon
    Neurosurgery.2023;[Epub]     CrossRef
  • Clinical Features, Management, and Prognostic Factors of Intracranial Solitary Fibrous Tumor
    Jingdian Liu, Sisi Wu, Kai Zhao, Junwen Wang, Kai Shu, Ting Lei
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Toward Better Understanding and Management of Solitary Fibrous Tumor
    Karineh Kazazian, Elizabeth G. Demicco, Marc de Perrot, Dirk Strauss, Carol J. Swallow
    Surgical Oncology Clinics of North America.2022; 31(3): 459.     CrossRef
  • Effect of Different Treatments for Intracranial Solitary Fibrous Tumors: Retrospective Analysis of 31 Patients
    Qinghua Li, Wenshuai Deng, Peng Sun
    World Neurosurgery.2022; 166: e60.     CrossRef
  • Sixteen-Year Follow-Up in a Cavernous Sinus Hemangiopericytoma: Improved Outcomes over Radiotherapy Advances
    Beatrice Detti, Lilia Bardoscia, Antonio Rosario Pisani, Salvatore Cozzi, Manuele Roghi, Paolo Mammucci, Angela Sardaro
    Brain Sciences.2022; 12(9): 1209.     CrossRef
  • Solitary Fibrous Tumor of the Jugular Foramen: A Case Report and Review of the Histopathologic Classification
    Mallory Raymond, Philip Ryan Elvis, Tiffany Baker, William Alexander Vandergrift, Theodore McRackan
    Otology & Neurotology.2022; 43(10): e1208.     CrossRef
  • A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons
    Javier Martin-Broto, Jose L. Mondaza-Hernandez, David S. Moura, Nadia Hindi
    Cancers.2021; 13(12): 2913.     CrossRef
  • Intradural Extramedullary Solitary Fibrous Tumor of the Thoracic Spinal Cord
    Zachary T Olmsted, Joanna Tabor, Omer Doron, Hossein Hosseini, Daniel Schneider, Ross Green, Samuel J Wahl, Daniel M Scuibba, Randy S D'Amico
    Cureus.2021;[Epub]     CrossRef
  • 8,441 View
  • 337 Download
  • 17 Web of Science
  • 20 Crossref
Close layer
Long-Term Outcomes and Sequelae Analysis of Intracranial Germinoma: Need to Reduce the Extended-Field Radiotherapy Volume and Dose to Minimize Late Sequelae
Joo Ho Lee, Keun-Yong Eom, Ji Hoon Phi, Chul-Kee Park, Seung Ki Kim, Byung-Kyu Cho, Tae Min Kim, Dae Seog Heo, Kyung Taek Hong, Jung Yoon Choi, Hyoung Jin Kang, Hee Young Shin, Seung Hong Choi, Soon Tae Lee, Sung Hye Park, Kyu-Chang Wang, Il Han Kim
Cancer Res Treat. 2021;53(4):983-990.   Published online January 13, 2021
DOI: https://doi.org/10.4143/crt.2020.1052
AbstractAbstract PDFPubReaderePub
Purpose
We aimed to refine the radiotherapy (RT) volume and dose for intracranial germinoma considering recurrences and long-term toxicities.
Materials and Methods
Total 189 patients with intracranial germinoma were treated with RT alone (n=50) and RT with upfront chemotherapy (CRT) (n=139). All cases were confirmed histologically. RT fields comprised the extended-field and involved-field only for primary site. The extended-field, including craniospinal, whole brain (WB), and whole ventricle (WV) for cranial field, is followed by involved-field boost. The median follow-up duration was 115 months.
Results
The relapses developed in 13 patients (6.9%). For the extended-field, cranial RT dose down to 18 Gy exhibited no cranial recurrence in 34 patients. In CRT, 74 patients (56.5%) showed complete response to chemotherapy and no involved-field recurrence with low-dose RT of 30 Gy. WV RT with chemotherapy for the basal ganglia or thalamus germinoma showed no recurrence. Secondary malignancy developed in 10 patients (5.3%) with a latency of 20 years (range, 4 to 26 years) and caused mortalities in six. WB or craniospinal field rather than WV or involved-field significantly increased the rate of hormone deficiencies, and secondary malignancy. RT dose for extended-field correlated significantly with the rate of hormone deficiencies, secondary malignancy, and neurocognitive dysfunction.
Conclusion
De-intensifying extended-field rather than involved-field or total scheme of RT will be critical to decrease the late toxicities. Upfront chemotherapy could be beneficial for the patients with complete response to minimize the RT dose down to 30 Gy. Prospective trials focused on de-intensification of the extended-field RT are warranted.

Citations

Citations to this article as recorded by  
  • NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors
    Eric Eunshik Kim, Chul-Kee Park, Seung-Ki Kim, Ji Hoon Phi, Sun Ha Paek, Jung Yoon Choi, Hyoung Jin Kang, Joo Ho Lee, Jae Kyung Won, Hongseok Yun, Sung-Hye Park
    Acta Neuropathologica Communications.2024;[Epub]     CrossRef
  • Clinical significance of cerebral microbleeds in patients with germinoma who underwent long-term follow-up
    Masayuki Kanamori, Shunji Mugikura, Osamu Iizuka, Naoko Mori, Yoshiteru Shimoda, Ichiyo Shibahara, Rei Umezawa, Keiichi Jingu, Ryuta Saito, Yukihiko Sonoda, Toshihiro Kumabe, Kyoko Suzuki, Hidenori Endo
    Journal of Neuro-Oncology.2024; 170(1): 173.     CrossRef
  • Excluding prepontine cistern from whole ventricle radiotherapy target volume in localized germinoma
    Hyejo Ryu, Joo Ho Lee
    Radiation Oncology Journal.2023; 41(1): 48.     CrossRef
  • Intracranial Germinomas: Diagnosis, Pathogenesis, Clinical Presentation, and Management
    Natalia Kremenevski, Michael Buchfelder, Nirjhar Hore
    Current Oncology Reports.2023; 25(7): 765.     CrossRef
  • Proton therapy for pediatric diencephalic tumors
    Adam J. Grippin, Susan L. McGovern
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Intracranial Germinoma—Association between Delayed Diagnosis, Altered Clinical Manifestations, and Prognosis
    Iwona Jabłońska, Marcin Goławski, Elżbieta Nowicka, Katarzyna Drosik-Rutowicz, Anna Trybus, Rafał Tarnawski, Marcin Miszczyk
    Cancers.2023; 15(10): 2789.     CrossRef
  • Outcomes of intracranial germinoma—A retrospective multinational Asian study on effect of clinical presentation and differential treatment strategies
    Kyung-Nam Koh, Ru Xin Wong, Dong-Eun Lee, Jung Woo Han, Hwa Kyung Byun, Hong In Yoon, Dong-Seok Kim, Chuhl Joo Lyu, Hyoung Jin Kang, Kyung Taek Hong, Joo Ho Lee, Il Han Kim, Ji Hoon Phi, Seung-Ki Kim, Tai-Tong Wong, Hsin-Lun Lee, I-Chun Lai, Yu-Mei Kang,
    Neuro-Oncology.2022; 24(8): 1389.     CrossRef
  • Photon versus proton whole ventricular radiotherapy for non‐germinomatous germ cell tumors: A report from the Children's Oncology Group
    David Y. Mak, Zain Siddiqui, Zhihui Amy Liu, Hitesh Dama, Shannon M. MacDonald, Shengjie Wu, Erin S. Murphy, Matthew D. Hall, Victor Malkov, Arzu Onar‐Thomas, Sameera Ahmed, Girish Dhall, Derek S. Tsang
    Pediatric Blood & Cancer.2022;[Epub]     CrossRef
  • Factors Influencing Craniospinal Relapse of Intracranial Germinoma After Complete Remission
    Takao Tsurubuchi, Kei Hara, Shingo Takano, Ai Muroi, Hiroko Fukushima, Masashi Mizumoto, Noriaki Sakamoto, Masahide Matsuda, Hiroyoshi Akutsu, Hideyuki Sakurai, Eiichi Ishikawa
    World Neurosurgery.2022; 166: e325.     CrossRef
  • Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Germinoma
    Cristina Ilcus, Horatiu Silaghi, Carmen Emanuela Georgescu, Carmen Georgiu, Anca Ileana Ciurea, Simona Delia Nicoara, Cristina Alina Silaghi
    Journal of Personalized Medicine.2021; 11(7): 661.     CrossRef
  • 10,720 View
  • 358 Download
  • 10 Web of Science
  • 10 Crossref
Close layer
Central nervous system
Clinical and Genomic Characteristics of Adult Diffuse Midline Glioma
Changhee Park, Tae Min Kim, Jeong Mo Bae, Hongseok Yun, Jin Wook Kim, Seung Hong Choi, Soon-Tae Lee, Joo Ho Lee, Sung-Hye Park, Chul-Kee Park
Cancer Res Treat. 2021;53(2):389-398.   Published online November 9, 2020
DOI: https://doi.org/10.4143/crt.2020.694
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The treatment outcomes and genomic profiles of diffuse midline glioma (DMG) in adult patients are rarely characterized. We performed a retrospective study to evaluate the clinicogenomic profiles of adult patients with brain DMG.
Materials and Methods
Patients aged ≥ 18 years diagnosed with brain DMG at Seoul National University Hospital were included. The clinicopathological parameters, treatment outcomes, survival, and genomic profiles using 82-gene targeted next-generation sequencing (NGS) were analyzed. The 6-month progression-free survival (PFS6) after radiotherapy and overall survival (OS) were evaluated.
Results
Thirty-three patients with H3-mutant brain DMG were identified. The median OS from diagnosis was 21.8 months (95% confidence interval [CI], 13.2 to not available [NA]) and involvement of the ponto-medullary area tended to have poor OS (median OS, 20.4 months [95% CI, 9.3 to NA] vs. 43.6 months [95% CI, 18.2 to NA]; p=0.07). Twenty-four patients (72.7%) received radiotherapy with or without temozolomide. The PFS6 rate was 83.3% (n=20). Patients without progression at 6 months showed significantly prolonged OS compared with those with progression at 6 months (median OS, 24.9 months [95% CI, 20.4 to NA] vs. 10.8 months [95% CI, 4.0 to NA]; p=0.02, respectively). Targeted NGS was performed in 13 patients with DMG, among whom nine (69.2%) harbored concurrent TP53 mutation. Two patients (DMG14 and DMG23) with PIK3CAR38S+E545K and KRASG12A mutations received matched therapies. Patient DMG14 received sirolimus with a PFS of 8.4 months.
Conclusion
PFS6 after radiotherapy was associated with prolonged survival in adult patients with DMG. Genome-based matched therapy may be an encouraging approach for progressive adult patients with DMG.

Citations

Citations to this article as recorded by  
  • The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study
    Vincenzo Di Nunno, Giuseppe Lombardi, Matteo Simonelli, Giuseppe Minniti, Angela Mastronuzzi, Valentina Di Ruscio, Martina Corrà, Marta Padovan, Marta Maccari, Mario Caccese, Giorgia Simonetti, Arianna Berlendis, Mariangela Farinotti, Bianca Pollo, Manila
    Journal of Neuro-Oncology.2024; 167(1): 145.     CrossRef
  • Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort
    Nobuhide Hayashi, Junya Fukai, Hirokazu Nakatogawa, Hiroshi Kawaji, Ema Yoshioka, Yoshinori Kodama, Kosuke Nakajo, Takehiro Uda, Kentaro Naito, Noriyuki Kijima, Yoshiko Okita, Naoki Kagawa, Yoshinobu Takahashi, Naoya Hashimoto, Hideyuki Arita, Koji Takano
    Acta Neuropathologica Communications.2024;[Epub]     CrossRef
  • How to treat histone 3 altered gliomas: molecular landscape and therapeutic developments
    Vincenzo Di Nunno, Enrico Franceschi, Lidia Gatto, Alicia Tosoni, Stefania Bartolini, Alba Ariela Brandes
    Expert Review of Clinical Pharmacology.2023; 16(1): 17.     CrossRef
  • Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
    Kwanghoon Lee, Seong-Ik Kim, Eric Eunshik Kim, Yu-Mi Shim, Jae-Kyung Won, Chul-Kee Park, Seung Hong Choi, Hongseok Yun, Hyunju Lee, Sung-Hye Park
    Scientific Reports.2023;[Epub]     CrossRef
  • Radiotherapy and radio‐sensitization in H3K27M‐mutated diffuse midline gliomas
    Chao Liu, Shuwen Kuang, Lei Wu, Quan Cheng, Xuan Gong, Jun Wu, Longbo Zhang
    CNS Neuroscience & Therapeutics.2023; 29(7): 1721.     CrossRef
  • Volumetric response and pattern of failure of histone altered high grade glioma in adults following management with radiation therapy
    A. Knight, P. Horsley, A. Yuile, J. Yim, M. Suh, V. Venketesha, M. Kastelan, H. Wheeler, M. Back
    Journal of Neuro-Oncology.2023; 163(1): 281.     CrossRef
  • Differences in survival prognosticators between children and adults with H3K27M‐mutant diffuse midline glioma
    Xuan Gong, Shuwen Kuang, Dongfeng Deng, Jun Wu, Longbo Zhang, Chao Liu
    CNS Neuroscience & Therapeutics.2023; 29(12): 3863.     CrossRef
  • Adult spinal cord diffuse midline glioma, H3 K27-altered mimics symptoms of central nervous system infection: a case report
    Xue Chen, Yi Li, Hui Bu, YueLi Zou, JunYing He, Hu Liu
    Frontiers in Neurology.2023;[Epub]     CrossRef
  • Clinicogenetic characteristics and the effect of radiation on the neural stem cell niche in subventricular zone-contacting glioblastoma
    Jee Ye Kahng, Byung-Hee Kang, Soon-Tae Lee, Seung Hong Choi, Tae Min Kim, Chul-Kee Park, Jae-Kyung Won, Sung-Hye Park, Jaeman Son, Joo Ho Lee
    Radiotherapy and Oncology.2023; 186: 109800.     CrossRef
  • H3 K27M-Altered Diffuse Midline Gliomas: A Review
    Karol Wiśniewski, Andrew Ghaly, Kate Drummond, Andreas Fahlstrӧm
    Indian Journal of Neurosurgery.2023; 12(02): 104.     CrossRef
  • Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity
    Carlos Axel López-Pérez, Xochitl Franco-Mojica, Ricardo Villanueva-Gaona, Alexandra Díaz-Alba, Marco Antonio Rodríguez-Florido, Victor Garcia Navarro
    Journal of Neuro-Oncology.2022; 158(3): 369.     CrossRef
  • H3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of Clinical Features and Survival Analysis
    Othman Bin-Alamer, Adrian E. Jimenez, Tej D. Azad, Chetan Bettegowda, Debraj Mukherjee
    World Neurosurgery.2022; 165: e251.     CrossRef
  • Molecular profile and clinical features of patients with gliomas using a broad targeted next generation‑sequencing panel
    Ourania Romanidou, Paraskevi Apostolou, Kyriakos Kouvelakis, Kyriakos Tsangaras, Alexia Eliades, Achilleas Achilleos, Charalambos Loizides, Christos Lemesios, Marios Ioannides, Elena Kypri, George Koumbaris, Kyriaki Papadopoulou, Athanasios Papathanasiou,
    Oncology Letters.2022;[Epub]     CrossRef
  • 8,330 View
  • 229 Download
  • 14 Web of Science
  • 13 Crossref
Close layer
A Nationwide, Population-Based Epidemiology Study of Primary Central Nervous System Tumors in Korea, 2007-2016: A Comparison with United States Data
Ho Kang, Sang Woo Song, Johyun Ha, Young-Joo Won, Chul-Kee Park, Heon Yoo, Kyu-Won Jung
Cancer Res Treat. 2021;53(2):355-366.   Published online October 7, 2020
DOI: https://doi.org/10.4143/crt.2020.847
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to determine the epidemiologic characteristics and survival of patients with primary brain and other central nervous system (CNS) tumors in Korea and to compare our findings with those from the United States.
Materials and Methods
We collected data on primary brain and CNS tumors diagnosed between 2007 and 2016 from the Korea Central Cancer Registry. The age-standardized incidence rates (ASRs) and 5-year relative survival rates (RSRs) were evaluated. We applied the classification and definitions of the Central Brain Tumor Registry of the United States to our analysis for direct comparison with United States data.
Results
A total of 115,050 primary brain and CNS tumors were identified, and the ASR of all tumors was 22.01 per 100,000 individuals, which was lower than the 23.41 in the United States. However, the ASR of malignant tumors was significantly lower herein (4.27) than in the United States (7.08). Meningeal tumors were the most common histologic group among all tumors (ASR, 8.32). The 5-year RSR of all primary brain and other CNS tumors was 86.4%, and that of all malignant tumors was 44.1%, which was higher than the 35.8% observed in the United States. Among malignant tumors, glioblastomas had the lowest 5-year RSR (12.1%).
Conclusion
In Korea, malignant brain and other CNS tumors have a lower incidence and better survival outcome.

Citations

Citations to this article as recorded by  
  • The Natural History and Treatment of Meningiomas: An Update
    Arsene Daniel Nyalundja, Fabrice Mugisha, Claire Karekezi
    Seminars in Neurology.2024; 44(01): 001.     CrossRef
  • Gamma knife radiosurgery as primary management for intracranial meningioma identified as growing on serial imaging
    Yeong Jin Kim, Kyung-Sub Moon, Sue Jee Park, Tae-Young Jung, In-Young Kim, Shin Jung
    Medicine.2024; 103(5): e37082.     CrossRef
  • Changes in the Epidemiologic Pattern of Primary CNS Tumors in Response to the Aging Population: An Updated Nationwide Cancer Registry Data in the Republic of Korea
    Yoon Hwan Byun, Johyun Ha, Ho Kang, Chul-Kee Park, Kyu-Won Jung, Heon Yoo
    JCO Global Oncology.2024;[Epub]     CrossRef
  • Surgical indications and outcomes of the endoscopic endonasal approach for brain tumors in older adults in Korea: a retrospective study
    Sun Mo Nam, Yoon Hwan Byun, Jung Hee Kim, Min-Sung Kim, Chul-Kee Park, Yong Hwy Kim
    Journal of Korean Society of Geriatric Neurosurgery.2024; 20(1): 21.     CrossRef
  • Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma: A Nationwide Population-Based Study
    Yeonhu Lee, Eunyoung Lee, Tae Hoon Roh, Se-Hyuk Kim
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Survival After Newly-Diagnosed High-Grade Glioma Surgery: What Can We Learn From the French National Healthcare Database?
    Charles Champeaux Depond, Luc Bauchet, Dahmane Elhairech, Philippe Tuppin, Vincent Jecko, Joconde Weller, Philippe Metellus
    Brain Tumor Research and Treatment.2024; 12(3): 162.     CrossRef
  • Comparative analysis of hypofractionated short-course versus standard radiation therapy in elderly patients with glioblastoma: analysis of nationwide database
    Yong Kyun Won, Eun Seog Kim, In Young Jo, Hyuk-jin Oh, Sang Mi Lee, Ik Dong Yoo, Sun-pyo Hong, Jeong Won Lee, Jin Ho Song, Nayoon Kang, Hong Seok Jang
    Journal of Neuro-Oncology.2024;[Epub]     CrossRef
  • Association between insomnia disorder and mortality among patients who underwent craniotomy for brain tumor resection: a South Korean nationwide cohort study
    Hey-ran Choi, In-Ae Song, Hye Yoon Park, Tak Kyu Oh
    Sleep and Breathing.2023; 27(1): 329.     CrossRef
  • Fully Automated MRI Segmentation and Volumetric Measurement of Intracranial Meningioma Using Deep Learning
    Ho Kang, Joseph Nathanael Witanto, Kevin Pratama, Doohee Lee, Kyu Sung Choi, Seung Hong Choi, Kyung‐Min Kim, Min‐Sung Kim, Jin Wook Kim, Yong Hwy Kim, Sang Joon Park, Chul‐Kee Park
    Journal of Magnetic Resonance Imaging.2023; 57(3): 871.     CrossRef
  • Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period
    Peter Y M Woo, Stephen Yau, Tai-Chung Lam, Jenny K S Pu, Lai-Fung Li, Louisa C Y Lui, Danny T M Chan, Herbert H F Loong, Michael W Y Lee, Rebecca Yeung, Carol C H Kwok, Siu-Kie Au, Tze-Ching Tan, Amanda N C Kan, Tony K T Chan, Calvin H K Mak, Henry K F Ma
    Neuro-Oncology Practice.2023; 10(1): 50.     CrossRef
  • Paths of Evolution of Progressive Anaplastic Meningiomas: A Clinical and Molecular Pathology Study
    Rina Di Bonaventura, Liverana Lauretti, Maurizio Martini, Tonia Cenci, Giuliano Di Monaco, Davide Palombi, Giovanni Maria Ceccarelli, Silvia Chiesa, Marco Gessi, Alessia Granitto, Alessio Albanese, Luigi Maria Larocca, Quintino Giorgio D’Alessandris, Robe
    Journal of Personalized Medicine.2023; 13(2): 206.     CrossRef
  • Intracranial Germinomas: Diagnosis, Pathogenesis, Clinical Presentation, and Management
    Natalia Kremenevski, Michael Buchfelder, Nirjhar Hore
    Current Oncology Reports.2023; 25(7): 765.     CrossRef
  • Decreased income, unemployment, and disability after craniotomy for brain tumor removal: a South Korean nationwide cohort study
    Tak Kyu Oh, In-Ae Song, Ji-Eyon Kwon, Solyi Lee, Hey-Ran Choi, Young-Tae Jeon
    Supportive Care in Cancer.2022; 30(2): 1663.     CrossRef
  • Association between surgical volume and outcomes after craniotomy for brain tumor removal: A South Korean nationwide cohort study
    Hey-ran Choi, In-Ae Song, Tak Kyu Oh
    Journal of Clinical Neuroscience.2022; 100: 75.     CrossRef
  • The comparative burden of brain and central nervous system cancers from 1990 to 2019 between China and the United States and predicting the future burden
    Jiajia Huang, Hanmei Li, Hualing Yan, Fen-Xiang Li, Mai Tang, Da-Lin Lu
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Anaplastic Meningioma: Clinical Characteristics, Prognostic Factors and Survival Outcome
    Dong Ok Seo, Sang Woo Song, Young-Hoon Kim, Chang-Ki Hong, Jeong Hoon Kim
    Brain Tumor Research and Treatment.2022; 10(4): 244.     CrossRef
  • Classification and Diagnosis of Adult Glioma: A Scoping Review
    Yoon Hwan Byun, Chul-Kee Park
    Brain & Neurorehabilitation.2022;[Epub]     CrossRef
  • Depression and mortality after craniotomy for brain tumor removal: A Nationwide cohort study in South Korea
    Tak Kyu Oh, In-Ae Song, Hye Yoon Park, Young-Tae Jeon
    Journal of Affective Disorders.2021; 295: 291.     CrossRef
  • 7,814 View
  • 209 Download
  • 18 Crossref
Close layer
Interim Tumor Progression and Volumetric Changes of Surgical Cavities during the Surgery-to-Radiotherapy Interval in Anaplastic Gliomas: Implications for Additional Pre-radiotherapy Magnetic Resonance Imaging
Chan Woo Wee, Il Han Kim, Chul-Kee Park, Jin Wook Kim
Cancer Res Treat. 2020;52(2):524-529.   Published online October 31, 2019
DOI: https://doi.org/10.4143/crt.2019.520
AbstractAbstract PDFPubReaderePub
Purpose
This study was designed to investigate the incidence of interim disease progression (IPD) and volumetric changes of the surgical cavity (SC) during the surgery-to-radiotherapy interval (SRI), and eventually assess the value of magnetic resonance imaging (MRI) at the time of radiotherapy (RT) planning in newly diagnosed anaplastic gliomas.
Materials and Methods
Among 195 anaplastic glioma patients who underwent RT, 121 were evaluable with two separate MRIs during SRI. The presence of IPD was determined using the updated Response Assessment in Neuro-Oncology size criteria. In 84 patients who underwent surgical resection, each SC was contoured by a radiation oncologist and the volumetric changes of the SCs were calculated between the two separate MRIs. Daily rate of change in the SC volume was calculated assuming an exponential and linear change.
Results
Five of 121 patients (4.13%) demonstrated IPD during SRI, and the incidence was significantly higher in patients undergoing biopsy (vs. surgical resection, 12.9% vs. 1.1%, p=0.015) and in patients with remnant contrast-enhancing tumor after surgery (15.8 vs. 2.0%, p=0.027). The mean daily rate of absolute change in SC was 1.06% (95% confidence interval [CI], 0.89 to 1.23) and 0.89% (95% CI, 0.77 to 1.02) according to the exponential and linear model, respectively. The expected mean volumetric change at 2 weeks were 16.64% (95% CI, 13.77 to 19.52) and 12.51% (95% CI, 10.77 to 14.26), respectively.
Conclusion
IPD during the SRI is rare in surgically resected anaplastic gliomas. However, pre-RT MRI is essential for accurate RT-target delineation and disease evaluation for patients initiating RT beyond postoperative 2 weeks and undergoing biopsy, respectively.

Citations

Citations to this article as recorded by  
  • Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma—an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial
    Stefan Dietzsch, Annett Braesigk, Clemens Seidel, Julia Remmele, Ralf Kitzing, Tina Schlender, Martin Mynarek, Dirk Geismar, Karolina Jablonska, Rudolf Schwarz, Montserrat Pazos, Damien C. Weber, Silke Frick, Kristin Gurtner, Christiane Matuschek, Semi Be
    Strahlentherapie und Onkologie.2022; 198(3): 282.     CrossRef
  • Effect of 3D Slicer Preoperative Planning and Intraoperative Guidance with Mobile Phone Virtual Reality Technology on Brain Glioma Surgery
    Jun Liu, Xiaodong Li, Xueping Leng, Bo Zhong, Yanhong Liu, Liang Liu, Mohammad Farukh Hashmi
    Contrast Media & Molecular Imaging.2022;[Epub]     CrossRef
  • 5,330 View
  • 165 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study)
Kihwan Hwang, Tae Min Kim, Chul-Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo, Yong-Kil Hong, Eun-Young Kim, Dong-Eun Lee, Jungnam Joo, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Seok-Gu Kang, Jeong Hoon Kim, Chae-Yong Kim
Cancer Res Treat. 2020;52(2):505-515.   Published online October 28, 2019
DOI: https://doi.org/10.4143/crt.2019.421
AbstractAbstract PDFPubReaderePub
Purpose
We investigated the efficacy of temozolomide during and after radiotherapy in Korean adults with anaplastic gliomas without 1p/19q co-deletion.
Materials and Methods
This was a randomized, open-label, phase 2 study and notably the first multicenter trial for Korean grade III glioma patients. Eligible patients were aged 18 years or older and had newly diagnosed non-co-deleted anaplastic glioma with an Eastern Cooperative Oncology Group performance status of 0-2. Patients were randomized 1:1 to receive radiotherapy alone (60 Gy in 30 fractions of 2 Gy) (control group, n=44) or to receive radiotherapy with concurrent temozolomide (75 mg/m2/day) followed by adjuvant temozolomide (150-200 mg/m2/day for 5 days during six 28-day cycles) (treatment group, n=40). The primary end-point was 2-year progression-free survival (PFS). Seventy patients (83.3%) were available for the analysis of the isocitrate dehydrogenase 1 gene (IDH1) mutation status.
Results
The two-year PFS was 42.2% in the treatment group and 37.2% in the control group. Overall survival (OS) did not reach to significant difference between the groups. In multivariable analysis, age was a significant risk factor for PFS (hazard ratio [HR], 2.08; 95% confidence interval [CI], 1.04 to 4.16). The IDH1 mutation was the only significant prognostic factor for PFS (HR, 0.28; 95% CI, 0.13 to 0.59) and OS (HR, 0.19; 95% CI, 0.07 to 0.50). Adverse events over grade 3 were seen in 16 patients (40.0%) in the treatment group and were reversible.
Conclusion
Concurrent and adjuvant temozolomide in Korean adults with newly diagnosed non-co- deleted anaplastic gliomas showed improved 2-year PFS. The survival benefit of this regimen needs further analysis with long-term follow-up at least more than 10 years.

Citations

Citations to this article as recorded by  
  • Multidisciplinary Management of Isocitrate Dehydrogenase–Mutated Gliomas in a Contemporary Molecularly Defined Era
    Rupesh Kotecha, David Schiff, Arnab Chakravarti, Jessica L. Fleming, Paul D. Brown, Vinay K. Puduvalli, Michael A. Vogelbaum, Vinai Gondi, Marco Gallus, Hideho Okada, Minesh P. Mehta
    Journal of Clinical Oncology.2024; 42(21): 2588.     CrossRef
  • The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas
    Connor J Kinslow, Soumyajit Roy, Fabio M Iwamoto, Paul D Brown, David M DeStephano, Peter D Canoll, Summer S Qureshi, Matthew Gallito, Michael B Sisti, Jeffrey N Bruce, David P Horowitz, Lisa A Kachnic, Alfred I Neugut, James B Yu, Minesh P Mehta, Simon K
    Neuro-Oncology.2024; 26(10): 1839.     CrossRef
  • The Role of Systemic Therapies in the Treatment of Grades 1-4 Gliomas
    Jan Stepka, Mariusz Dotka, Maciej Kosiński, Piotr Suchecki, Maciej Hobot, Igor Piotrowski
    Cureus.2024;[Epub]     CrossRef
  • Impact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ
    Jordina Rincon-Torroella, Maureen Rakovec, Anita L. Kalluri, Kelly Jiang, Carly Weber-Levine, Megan Parker, Divyaansh Raj, Josh Materi, Sadra Sepehri, Abel Ferres, Karisa C. Schreck, Iban Aldecoa, Calixto-Hope G. Lucas, Haris I. Sair, Kristin J. Redmond,
    Journal of Neuro-Oncology.2024;[Epub]     CrossRef
  • Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
    Nimish A. Mohile, Hans Messersmith, Na Tosha Gatson, Andreas F. Hottinger, Andrew Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olson, James Perry, Jana Portnow, David Schiff, Anne Shannon, Helen A. Shih, Roy Strowd, M
    Journal of Clinical Oncology.2022; 40(4): 403.     CrossRef
  • Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
    Nimish A Mohile, Hans Messersmith, Na Tosha N Gatson, Andreas F Hottinger, Andrew B Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olson, James Perry, Jana Portnow, David Schiff, Anne Shannon, Helen A Shih, Roy Strowd,
    Neuro-Oncology.2022; 24(3): 358.     CrossRef
  • Executive summary of American Radium Society’s appropriate use criteria for the postoperative management of lower grade gliomas
    Martin C. Tom, Michael T. Milano, Samuel T. Chao, Scott G. Soltys, Jonathan P.S. Knisely, Arjun Sahgal, Seema Nagpal, Simon S. Lo, Siavash Jabbari, Tony J.C. Wang, Manmeet S. Ahluwalia, Marian Simonson, Joshua D. Palmer, Melanie Hayden Gephart, Lia M. Hal
    Radiotherapy and Oncology.2022; 170: 79.     CrossRef
  • Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)
    Grace S. Ahn, Kihwan Hwang, Tae Min Kim, Chul Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo, Yong-Kil Hong, Eun-Young Kim, Dong-Eun Lee, Jungnam Joo, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Seok-Gu Kang, Jeo
    Cancer Research and Treatment.2022; 54(2): 396.     CrossRef
  • The Risk of Heart Disease-Related Death Among Anaplastic Astrocytoma Patients After Chemotherapy: A SEER Population-Based Analysis
    Qi Lin, Jia-Hao Bao, Fei Xue, Jia-Jun Qin, Zhen Chen, Zhong-Rong Chen, Chao Li, Yi-Xuan Yan, Jin Fu, Zhao-Li Shen, Xian-Zhen Chen
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Association between a prior cancer history and prognosis in adult patients with high‑grade glioma
    Dongjie He, Peiwen Wu, Gaiyan Li, Siying Zhu, Qiming Wang, Qiuju Shao, Hao Chang
    Journal of Clinical Neuroscience.2022; 106: 20.     CrossRef
  • 9,305 View
  • 635 Download
  • 9 Web of Science
  • 10 Crossref
Close layer
Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma
Young-Bem Se, Seung Hyun Kim, Ji Young Kim, Ja Eun Kim, Yun-Sik Dho, Jin Wook Kim, Yong Hwy Kim, Hyun Goo Woo, Se-Hyuk Kim, Shin-Hyuk Kang, Hak Jae Kim, Tae Min Kim, Soon-Tae Lee, Seung Hong Choi, Sung-Hye Park, Il Han Kim, Dong Gyu Kim, Chul-Kee Park
Cancer Res Treat. 2017;49(2):387-398.   Published online July 19, 2016
DOI: https://doi.org/10.4143/crt.2016.106
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Homeobox (HOX) genes are essential developmental regulators that should normally be in the silenced state in an adult brain. The aberrant expression of HOX genes has been associated with the prognosis of many cancer types, including glioblastoma (GBM). This study examined the identity and role of HOX genes affecting GBM prognosis and treatment resistance.
Materials and Methods
The full series of HOX genes of five pairs of initial and recurrent human GBM samples were screened by microarray analysis to determine the most plausible candidate responsible for GBM prognosis. Another 20 newly diagnosed GBM samples were used for prognostic validation. In vitro experiments were performed to confirm the role of HOX in treatment resistance. Mediators involved in HOX gene regulation were searched using differentially expressed gene analysis, gene set enrichment tests, and network analysis.
Results
The underexpression of HOXA11 was identified as a consistent signature for a poor prognosis among the HOX genes. The overall survival of the GBM patients indicated a significantly favorable prognosis in patients with high HOXA11 expression (31±15.3 months) compared to the prognoses in thosewith lowHOXA11 expression (18±7.3 months, p=0.03). When HOXA11 was suppressed in the GBM cell lines, the anticancer effect of radiotherapy and/or temozolomide declined. In addition, five candidate mediators (TGFBR2, CRIM1, TXNIP, DPYSL2, and CRMP1) that may confer an oncologic effect after HOXA11 suppression were identified.
Conclusion
The treatment resistance induced by the underexpression of HOXA11 can contribute to a poor prognosis in GBM. Further investigation will be needed to confirm the value of HOXA11 as a potential target for overcoming the treatment resistance by developing chemo- or radiosensitizers.

Citations

Citations to this article as recorded by  
  • Intratumoral IL-12 delivery via mesenchymal stem cells combined with PD-1 blockade leads to long-term antitumor immunity in a mouse glioblastoma model
    Junseong Park, Soon A. Park, Yoon-Seob Kim, Dokyeong Kim, Sun Shin, Sug Hyung Lee, Sin-Soo Jeun, Yeun-Jun Chung, Stephen Ahn
    Biomedicine & Pharmacotherapy.2024; 173: 115790.     CrossRef
  • Dihydropyrimidinase‐like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia
    Fenglin Li, Qing Ling, Jiaying Lian, Ying Chen, Chao Hu, Min Yang, Xiang Zhang, Chenying Li, Shihui Mao, Wenle Ye, Xia Li, Xiangjie Lin, Wenwen Wei, Xin Huang, Jiajia Pan, Yu Qian, Jinghan Wang, Ying Lu, Jie Jin
    Cancer Medicine.2023; 12(7): 8319.     CrossRef
  • Development and validation of a predictive model in diagnosis and prognosis of primary glioblastoma patients based on Homeobox A family
    Zong-Qing Zheng, Gui-Qiang Yuan, Guo-Guo Zhang, Qian-Qian Nie, Zhong Wang
    Discover Oncology.2023;[Epub]     CrossRef
  • HOXA11-AS aggravates microglia-induced neuroinflammation after traumatic brain injury
    Xiang-Long Li, Bin Wang, Fu-Bing Yang, Li-Gang Chen, Jian You
    Neural Regeneration Research.2022; 17(5): 1096.     CrossRef
  • Molecular implications of HOX genes targeting multiple signaling pathways in cancer
    U Sangeetha Shenoy, Divya Adiga, Shama Prasada Kabekkodu, Keith D Hunter, Raghu Radhakrishnan
    Cell Biology and Toxicology.2022; 38(1): 1.     CrossRef
  • High expression ofHOXA4in patients with glioma indicates unfavorable clinical outcomes
    Zhenghong Yu, Zhendong Liu, Xiaoyu Lian, Xingbo Cheng, Binfeng Liu, Bo Zhang, Hongbo Wang, Jialin Wang, Ang Li, Zhishuai Ren, Bo Pang, Rongjun Qian, Yanzheng Gao
    Cell Cycle.2022; 21(22): 2387.     CrossRef
  • Downregulation of HOXA11 enhances endometrial cancer malignancy and cisplatin resistance via activating PTEN/AKT signaling pathway
    C. Kong, Z. Zhu, Y. Li, P. Xue, L. Chen
    Clinical and Translational Oncology.2021; 23(7): 1334.     CrossRef
  • Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review
    Sara Momtazmanesh, Nima Rezaei
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
    Srikumar Chakravarthi, Barani Karikalan
    Current Cancer Therapy Reviews.2021; 17(2): 97.     CrossRef
  • HOX gene cluster (de)regulation in brain: from neurodevelopment to malignant glial tumours
    Céline S. Gonçalves, Elisa Le Boiteux, Philippe Arnaud, Bruno M. Costa
    Cellular and Molecular Life Sciences.2020; 77(19): 3797.     CrossRef
  • Expression Profile and Prognostic Values of HOXA Family Members in Laryngeal Squamous Cell Cancer
    Jinyun Li, Meng Ye, Chongchang Zhou
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Methylation in HOX Clusters and Its Applications in Cancer Therapy
    Ana Paço, Simone Aparecida de Bessa Garcia, Renata Freitas
    Cells.2020; 9(7): 1613.     CrossRef
  • N6-Methylandenosine-Related lncRNAs Are Potential Biomarkers for Predicting the Overall Survival of Lower-Grade Glioma Patients
    Zewei Tu, Lei Wu, Peng Wang, Qing Hu, Chuming Tao, Kuangxun Li, Kai Huang, Xingen Zhu
    Frontiers in Cell and Developmental Biology.2020;[Epub]     CrossRef
  • Targeting HOX/PBX dimer formation as a potential therapeutic option in esophageal squamous cell carcinoma
    Lu‐Yan Shen, Ting Zhou, Ya‐Bing Du, Qi Shi, Ke‐Neng Chen
    Cancer Science.2019; 110(5): 1735.     CrossRef
  • An inverse interaction betweenHOXA11andHOXA11-ASis associated with cisplatin resistance in lung adenocarcinoma
    Youwei Zhang, Yuan Yuan, Yang Li, Peiying Zhang, Pingsheng Chen, Sanyuan Sun
    Epigenetics.2019; 14(10): 949.     CrossRef
  • Long noncoding RNA HOXA11-AS promotes gastric cancer cell proliferation and invasion via SRSF1 and functions as a biomarker in gastric cancer
    Yun Liu, Yu-Mei Zhang, Feng-Bo Ma, Su-Rong Pan, Bao-Zhen Liu
    World Journal of Gastroenterology.2019; 25(22): 2763.     CrossRef
  • DNA methylation changes following DNA damage in prostate cancer cells
    Laura P. Sutton, Sarah A. Jeffreys, Jessica L. Phillips, Phillippa C. Taberlay, Adele F. Holloway, Mark Ambrose, Ji-Hoon E. Joo, Arabella Young, Rachael Berry, Marketa Skala, Kate H. Brettingham-Moore
    Epigenetics.2019; 14(10): 989.     CrossRef
  • MicroRNA‐128/homeobox B8 axis regulates ovarian cancer cell progression
    Rui Li, Lingling Gong, Pin Li, Jing Wang, Liangliang Bi
    Basic & Clinical Pharmacology & Toxicology.2019; 125(6): 499.     CrossRef
  • Evaluation of the HOXA11 level in patients with lung squamous cancer and insights into potential molecular pathways via bioinformatics analysis
    Rui Zhang, Tong-tong Zhang, Gao-qiang Zhai, Xian-yu Guo, Yuan Qin, Ting-qing Gan, Yu Zhang, Gang Chen, Wei-jia Mo, Zhen-bo Feng
    World Journal of Surgical Oncology.2018;[Epub]     CrossRef
  • HOXA11 antisense long noncoding RNA (HOXA11‐AS): A promising lncRNA in human cancers
    Cheng‐Wei Lu, Dan‐Dan Zhou, Tian Xie, Ji‐Long Hao, Om Prakash Pant, Cheng‐Bo Lu, Xiu‐Fen Liu
    Cancer Medicine.2018; 7(8): 3792.     CrossRef
  • Identification of radiation responsive genes and transcriptome profiling via complete RNA sequencing in a stable radioresistant U87 glioblastoma model
    Ninh B. Doan, Ha S. Nguyen, Hisham S. Alhajala, Basem Jaber, Mona M. Al-Gizawiy, Eun-Young Erin Ahn, Wade M. Mueller, Christopher R. Chitambar, Shama P. Mirza, Kathleen M. Schmainda
    Oncotarget.2018; 9(34): 23532.     CrossRef
  • Upregulation of HOXA11 during the progression of lung adenocarcinoma detected via multiple approaches
    Xia Yang, Yun Deng, Rong‑Quan He, Xiao‑Jiao Li, Jie Ma, Gang Chen, Xiao‑Hua Hu
    International Journal of Molecular Medicine.2018;[Epub]     CrossRef
  • Clinical Significance and Effect of lncRNA HOXA11-AS in NSCLC: A Study Based on Bioinformatics, In Vitro and in Vivo Verification
    Yu Zhang, Wen-jie Chen, Ting-qing Gan, Xiu-ling Zhang, Zu-cheng Xie, Zhi-hua Ye, Yun Deng, Ze-feng Wang, Kai-teng Cai, Shi-kang Li, Dian-zhong Luo, Gang Chen
    Scientific Reports.2017;[Epub]     CrossRef
  • Functional analysis of HOXA10 and HOXB4 in human medulloblastoma cell lines
    Ricardo Bonfim-Silva, Fernanda Ursoli Ferreira Melo, Carolina Hassibe Thomé, Kuruvilla Joseph Abraham, Fábio Augusto Labre De Souza, Fernando Silva Ramalho, Hélio Rubens Machado, Ricardo Santos De Oliveira, Angelo A. Cardoso, Dimas Tadeu Covas, Aparecida
    International Journal of Oncology.2017; 51(6): 1929.     CrossRef
  • Long non-coding RNA HOXA11-AS promotes cell proliferation and metastasis in human breast cancer
    Jian-Chun Su, Xue-Feng Hu
    Molecular Medicine Reports.2017; 16(4): 4887.     CrossRef
  • Identification of skin-related lncRNAs as potential biomarkers that are involved in Wnt pathways in keloids
    Xiao-Jie Sun, Qiang Wang, Baofeng Guo, Xian-Ying Liu, Bing Wang
    Oncotarget.2017; 8(21): 34236.     CrossRef
  • Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia
    Hongmei Luo, Yu Qin, Frederic Reu, Sujuan Ye, Yang Dai, Jingcao Huang, Fangfang Wang, Dan Zhang, Ling Pan, Huanling Zhu, Yu Wu, Ting Niu, Zhijian Xiao, Yuhuan Zheng, Ting Liu
    Journal of Hematology & Oncology.2016;[Epub]     CrossRef
  • 14,605 View
  • 329 Download
  • 30 Web of Science
  • 27 Crossref
Close layer
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
Byung Sup Kim, Ho Jun Seol, Do-Hyun Nam, Chul-Kee Park, Il Han Kim, Tae Min Kim, Jeong Hoon Kim, Young Hyun Cho, Sang Min Yoon, Jong Hee Chang, Seok-Gu Kang, Eui Hyun Kim, Chang-Ok Suh, Tae-Young Jung, Kyung-Hwa Lee, Chae-Yong Kim, In Ah Kim, Chang-Ki Hong, Heon Yoo, Jin Hee Kim, Shin-Hyuk Kang, Min Kyu Kang, Eun-Young Kim, Sun-Hwan Kim, Dong-Sup Chung, Sun-Chul Hwang, Joon-Ho Song, Sung Jin Cho, Sun-Il Lee, Youn-Soo Lee, Kook-Jin Ahn, Se Hoon Kim, Do Hun Lim, Ho-Shin Gwak, Se-Hoon Lee, Yong-Kil Hong
Cancer Res Treat. 2017;49(1):193-203.   Published online June 27, 2016
DOI: https://doi.org/10.4143/crt.2015.473
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample.
Materials and Methods
A total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who received concurrent chemoradiotherapy with TMZ (CCRT) and adjuvant TMZ from January 2006 until June 2011, were analyzed retrospectively.
Results
After the first operation, a gross total resection (GTR), subtotal resection (STR), partial resection (PR), biopsy alone were achieved in 388 (51.7%), 159 (21.2%), 96 (12.8%), and 107 (14.3%) patients,respectively. The methylation status of O6-methylguanine-DNA methyltransferase (MGMT) was reviewed retrospectively in 217 patients. The median follow-up period was 16.3 months and the median overall survival (OS) was 17.5 months. The actuarial survival rates at the 1-, 3-, and 5-year OS were 72.1%, 21.0%, and 9.0%, respectively. The median progression-free survival (PFS) was 10.1 months, and the actuarial PFS at 1-, 3-, and 5-year PFS were 42.2%, 13.0%, and 7.8%, respectively. The patients who received GTR showed a significantly longer OS and PFS than those who received STR, PR, or biopsy alone, regardless of the methylation status of the MGMT promoter. Patients with a methylated MGMT promoter also showed a significantly longer OS and PFS than those with an unmethylated MGMT promoter. Patients who received more than six cycles of adjuvant TMZ had a longer OS and PFS than those who received six or fewer cycles. Hematologic toxicity of grade 3 or 4 was observed in 8.4% of patients during the CCRT period and in 10.2% during the adjuvant TMZ period.
Conclusion
Patients treated with CCRT followed by adjuvant TMZ had more favorable survival rates and tolerable toxicity than those who did not undergo this treatment.

Citations

Citations to this article as recorded by  
  • Letter to the Editor Regarding Cerebral Blood Flow Role in Delineating Treatment Effect from True Tumor Progression in Glioblastoma Multiforme
    Inibehe Ime Okon, Tolulope Judah Gbayisomore, Samuel Berchi Kankam, Mohammad Jalloh
    World Neurosurgery.2024; 186: 269.     CrossRef
  • NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors
    Eric Eunshik Kim, Chul-Kee Park, Seung-Ki Kim, Ji Hoon Phi, Sun Ha Paek, Jung Yoon Choi, Hyoung Jin Kang, Joo Ho Lee, Jae Kyung Won, Hongseok Yun, Sung-Hye Park
    Acta Neuropathologica Communications.2024;[Epub]     CrossRef
  • The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Recommendation Using the Delphi Method (Version 2023.1)
    Min-Sung Kim, Se-Il Go, Chan Woo Wee, Min Ho Lee, Seok-Gu Kang, Kyeong-O Go, Sae Min Kwon, Woohyun Kim, Yun-Sik Dho, Sung-Hye Park, Youngbeom Seo, Sang Woo Song, Stephen Ahn, Hyuk-Jin Oh, Hong In Yoon, Sea-Won Lee, Joo Ho Lee, Kyung Rae Cho, Jung Won Choi
    Brain Tumor Research and Treatment.2023; 11(2): 123.     CrossRef
  • Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges
    Daisuke Sato, Hirokazu Takami, Shunsaku Takayanagi, Kazuki Taoka, Mariko Tanaka, Reiko Matsuura, Shota Tanaka, Nobuhito Saito
    BMC Neurology.2023;[Epub]     CrossRef
  • Glioma angiogenesis is boosted by ELK3 activating the HIF-1$$alpha$$/VEGF-A signaling axis
    Mou Yueyang, Hu Yaqin, Xue Guolian, Zhao Wenjian, Jiao Yang, Li Chen, Cao Haiyan, Chao Min, Deng Jianping, Dai Penggao, Zhu Hongli, Wang Liang
    BMC Cancer.2023;[Epub]     CrossRef
  • Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open‐label phase 2 study
    Kihwan Hwang, Junhyung Kim, Seok‐Gu Kang, Tae‐Young Jung, Jeong Hoon Kim, Se‐Hyuk Kim, Shin‐Hyuk Kang, Yong‐Kil Hong, Tae Min Kim, Yu Jung Kim, Byung Se Choi, Jong Hee Chang, Chae‐Yong Kim
    Cancer Medicine.2022; 11(2): 371.     CrossRef
  • Prognostic Value and Risk Factors of Treatment-Related Lymphopenia in Malignant Glioma Patients Treated With Chemoradiotherapy: A Systematic Review and Meta-Analysis
    Yongchao Zhang, Shichao Chen, Hualei Chen, Shanshan Chen, Zhen Li, Enshan Feng, Wei Li
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • PrACTiC: A Predictive Algorithm for Chemoradiotherapy-Induced Cytopenia in Glioblastoma Patients
    Alireza Amouheidari, Zahra Alirezaei, Stefan Rauh, Masoud Hassanpour, Ozkan Kanat
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Relapsing High—Grade Glioma from Peritumoral Zone: Critical Review of Radiotherapy Treatment Options
    Maria Chiara Lo Greco, Roberto Milazzotto, Rocco Luca Emanuele Liardo, Grazia Acquaviva, Madalina La Rocca, Roberto Altieri, Francesco Certo, Giuseppe Maria Barbagallo, Antonio Basile, Pietro Valerio Foti, Stefano Palmucci, Stefano Pergolizzi, Antonio Pon
    Brain Sciences.2022; 12(4): 416.     CrossRef
  • Effect of Choline Alphoscerate on the Survival of Glioblastoma Patients: A Retrospective, Single-Center Study
    Yeong Jin Kim, Tae-Kyu Lee, Myung-Giun Noh, Tae-Young Jung, In-Young Kim, Shin Jung, Kyung-Hwa Lee, Kyung-Sub Moon
    Journal of Clinical Medicine.2022; 11(20): 6052.     CrossRef
  • Evaluating survival in subjects with astrocytic brain tumors by dynamic susceptibility-weighted perfusion MR imaging
    Matthew L. White, Yan Zhang, Syed A. Jaffar Kazmi, Michele Aizenberg, Nicole Shonka, Fang Yu, Adams Kusi Appiah, Michael C. Burger
    PLOS ONE.2021; 16(1): e0244275.     CrossRef
  • Prognostic value of test(s) for O6-methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
    Alexandra McAleenan, Claire Kelly, Francesca Spiga, Ashleigh Kernohan, Hung-Yuan Cheng, Sarah Dawson, Lena Schmidt, Tomos Robinson, Sebastian Brandner, Claire L Faulkner, Christopher Wragg, Sarah Jefferies, Amy Howell, Luke Vale, Julian P T Higgins, Kathr
    Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
  • Mixed malignant glioblastoma and schwannoma in spinal cord with metachronous ependymoma: A case report
    Mostafa Farzin, Mohamadreza Hajiabadi, Mohammad Rahmani, Kasra Kolahdouzan
    Clinical Case Reports.2021;[Epub]     CrossRef
  • Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study
    Srinivas Annavarapu, Anagha Gogate, Trang Pham, Kalatu Davies, Prianka Singh, Nicholas Robert
    CNS Oncology.2021;[Epub]     CrossRef
  • A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
    Fahimeh Attarian, Farzad Taghizadeh-Hesary, Azar Fanipakdel, Seyed Alireza Javadinia, Pejman Porouhan, Babak PeyroShabany, Danial Fazilat-Panah
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial
    Chae-Yong Kim, Sun Ha Paek, Do-hyun Nam, Jong-Hee Chang, Yong-Kil Hong, Jeong Hoon Kim, Oh Lyong Kim, Se-Hyuk Kim
    Journal of Neuro-Oncology.2020; 146(3): 399.     CrossRef
  • Risk Factors for Cognitive Impairment in High-Grade Glioma Patients Treated with Postoperative Radiochemotherapy
    Qiang Wang, Fengxia Xiao, Fei Qi, Xiaopeng Song, Yonghua Yu
    Cancer Research and Treatment.2020; 52(2): 586.     CrossRef
  • Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
    Maria B. Garcia-Fabiani, Maria Ventosa, Andrea Comba, Marianela Candolfi, Alejandro J. Nicola Candia, Mahmoud S. Alghamri, Padma Kadiyala, Stephen Carney, Syed M. Faisal, Anna Schwendeman, James J. Moon, Lindsay Scheetz, Joerg Lahann, Ava Mauser, Pedro R.
    Expert Opinion on Investigational Drugs.2020; 29(7): 659.     CrossRef
  • Long Intergenic Non-Protein Coding RNA 1094 Promotes Initiation and Progression of Glioblastoma by Promoting microRNA-577-Regulated Stabilization of Brain-Derived Neurotrophic Factor


    Xiaoyan Dong, Xiuxin Fu, Miao Yu, Zengfen Li
    Cancer Management and Research.2020; Volume 12: 5619.     CrossRef
  • SNHG7 Facilitates Glioblastoma Progression by Functioning as a Molecular Sponge for MicroRNA-449b-5p and Thereby Increasing MYCN Expression
    Yaogang Chen, Shaoyong Yuan, Tieying Ning, Huiqing Xu, Bo Guan
    Technology in Cancer Research & Treatment.2020;[Epub]     CrossRef
  • Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres
    Hyeong-Cheol Oh, Jin-Kyoung Shim, Junseong Park, Ji-Hyun Lee, Ran Joo Choi, Nam Hee Kim, Hyun Sil Kim, Ju Hyung Moon, Eui Hyun Kim, Jong Hee Chang, Jong In Yook, Seok-Gu Kang
    Journal of Cancer Research and Clinical Oncology.2020; 146(11): 2817.     CrossRef
  • Clinical Characteristics of High-Grade Glioma with Primary Leptomeningeal Seeding at Initial Diagnosis in a Single Center Study
    Ji-Eyon Kwon, Kihwan Hwang, Kyeong-O Go, Chan Woo Wee, In Ah Kim, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Jung Ho Han, Chae-Yong Kim
    Brain Tumor Research and Treatment.2020; 8(2): 77.     CrossRef
  • A Longitudinal Study of Lipid Peroxidation and Symptom Clusters in Patients With Brain Cancers
    Sanghee Kim
    Nursing Research.2018; 67(5): 387.     CrossRef
  • Dynamic Susceptibility Contrast (DSC) Perfusion MR in the Prediction of Long-Term Survival of Glioblastomas (GBM): Correlation with MGMT Promoter Methylation and 1p/19q Deletions
    Yong Wonn Kwon, Won-Jin Moon, Mina Park, Hong Gee Roh, Young Cho Koh, Sang Woo Song, Jin Woo Choi
    Investigative Magnetic Resonance Imaging.2018; 22(3): 158.     CrossRef
  • Notch1ablation radiosensitizes glioblastoma cells
    Na Han, Guangyuan Hu, Lei Shi, Guoxian Long, Lin Yang, Qingsong Xi, Qiuyun Guo, Jianhua Wang, Zhen Dong, Mengxian Zhang
    Oncotarget.2017; 8(50): 88059.     CrossRef
  • Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system
    Haihui Jiang, Yong Cui, Junmei Wang, Song Lin
    Oncotarget.2017; 8(12): 20354.     CrossRef
  • 15,662 View
  • 314 Download
  • 23 Web of Science
  • 26 Crossref
Close layer
Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma
Yongjun Cha, Yu Jung Kim, Se-Hoon Lee, Tae-Min Kim, Seung Hong Choi, Dong-Wan Kim, Chul-Kee Park, Il Han Kim, Jee Hyun Kim, Eunhee Kim, Byungse Choi, Chae-Yong Kim, In Ah Kim, Dae Seog Heo
Cancer Res Treat. 2017;49(1):129-140.   Published online May 18, 2016
DOI: https://doi.org/10.4143/crt.2015.466
AbstractAbstract PDFPubReaderePub
Purpose
Bevacizumab±irinotecan is effective for treatment of recurrent malignant gliomas. However, the optimal duration of treatment has not been established.
Materials and Methods
Ninety-four consecutive patients with recurrent malignant glioma who were treated with bevacizumab at our institutions were identified. Patients who continued bevacizumab until tumor progression were enrolled in a late discontinuation (LD) group, while those who stopped bevacizumab before tumor progression were enrolled in an early discontinuation (ED) group. Landmark analyses were performed at weeks 9, 18, and 26 for comparison of patient survival between the two groups.
Results
Among 89 assessable patients, 62 (69.7%) and 27 (30.3%) patients were categorized as the LD and ED groups, respectively. According to landmark analysis, survival times from weeks 9, 18, and 26 were not significantly different between the two groups in the overall population. However, the LD group showed a trend toward increased survival compared to the ED group among responders. In the ED group, the median time from discontinuation to disease progression was 11.4 weeks, and none of the patients showed a definite rebound phenomenon. Similar median survival times after disease progression were observed between groups (14.4 weeks vs. 15.7 weeks, p=0.251). Of 83 patients, 38 (45.8%) received further therapy at progression, and those who received further therapy showed longer survival in both the LD and ED groups.
Conclusion
In recurrent malignant glioma, duration of bevacizumab was not associated with survival time in the overall population. However, ED of bevacizumab in responding patients might be associated with decreased survival.

Citations

Citations to this article as recorded by  
  • The Vascular Microenvironment in Glioblastoma: A Comprehensive Review
    Alejandra Mosteiro, Leire Pedrosa, Abel Ferrés, Diouldé Diao, Àngels Sierra, José Juan González
    Biomedicines.2022; 10(6): 1285.     CrossRef
  • Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors
    Tiziana Annese, Mariella Errede, Antonio d’Amati, Michelina De Giorgis, Loredana Lorusso, Roberto Tamma, Domenico Ribatti
    Diagnostics.2022; 12(12): 3120.     CrossRef
  • Identification of diverse tumor endothelial cell populations in malignant glioma
    Jeff C Carlson, Manuel Cantu Gutierrez, Brittney Lozzi, Emmet Huang-Hobbs, Williamson D Turner, Burak Tepe, Yiqun Zhang, Alexander M Herman, Ganesh Rao, Chad J Creighton, Joshua D Wythe, Benjamin Deneen
    Neuro-Oncology.2021; 23(6): 932.     CrossRef
  • Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy
    Charlotte Bronnimann, Cristina Izquierdo, Stéphanie Cartalat, Laure Thomas, Bastien Joubert, Laura Delpech, Marc Barritault, David Meyronet, Jérôme Honnorat, François Ducray
    Journal of Neuro-Oncology.2018; 138(1): 141.     CrossRef
  • 10,079 View
  • 181 Download
  • 5 Web of Science
  • 4 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP